Trending
Analyzing the Price-to-Earnings Ratio of Allogene Therapeutics Inc (ALLO)
The 36-month beta value for ALLO is also noteworthy at 0.32. There are mixed opinions on the stock, with 8 analysts rating it as a
The 36-month beta value for ALLO is also noteworthy at 0.32. There are mixed opinions on the stock, with 8 analysts rating it as a
Allogene Therapeutics Inc (NASDAQ: ALLO) has experienced a rise in its stock price by 2.69 compared to its previous closing price of 1.30. However, the
Additionally, the 36-month beta value for ALLO is 0.32. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4
ALLO has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,”
Allogene Therapeutics Inc (NASDAQ: ALLO)’s stock price has soared by 1.89 in relation to previous closing price of 1.06. Nevertheless, the company has seen a
© 2024, Powered by Smart TechOne